Cargando…

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men

CONTEXT: A novel formulation of oral testosterone (T) undecanoate (TU) was evaluated in a phase 3 clinical trial. OBJECTIVE: Determine efficacy, short-term safety, and alignment of new oral TU formulation with current US approval standards for T replacement therapy. DESIGN: Randomized, active-contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swerdloff, Ronald S, Wang, Christina, White, William B, Kaminetsky, Jed, Gittelman, Marc C, Longstreth, James A, Dudley, Robert E, Danoff, Theodore M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282712/ https://www.ncbi.nlm.nih.gov/pubmed/32382745 http://dx.doi.org/10.1210/clinem/dgaa238

Ejemplares similares

Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2021)

SUN-227 Monitoring Testosterone (T) Levels in Men Receiving Oral Testosterone Undecanoate (TU): Challenges Due to Post-Collection Conversion of TU-to-T and a Path Forward
por: Swerdloff, Ronald, et al.
Publicado: (2019)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020)

SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

PMON267 Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®)
por: Swerdloff, Ronald, et al.
Publicado: (2022)

Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men
por: White, William B., et al.
Publicado: (2021)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men
Publicado: (2021)

SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate
por: Dobs, Adrian Sandra, et al.
Publicado: (2020)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single‐Use Autoinjector: A Phase II Study
por: Kaminetsky, Jed, et al.
Publicado: (2015)

OR25-06 The Effect of Testosterone Replacement Therapy on NAFLD in Elderly Hypogonadal Men
por: Seung Lee, Hae, et al.
Publicado: (2023)

UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism
por: Bang, Anne Kirstine, et al.
Publicado: (2013)

Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021)

Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement Therapy
por: Surampudi, Prasanth N., et al.
Publicado: (2012)

Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights
por: Campbell, Katherine, et al.
Publicado: (2023)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

Spectrophotometric and chromatographic strategies for exploring of the nanostructure pharmaceutical formulations which contains testosterone undecanoate
por: Butnariu, Monica, et al.
Publicado: (2020)

Oral testosterone undecanoate is an effective treatment for micropenis therapy
por: Saenger, Paul, et al.
Publicado: (2021)

Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats
por: An, Jinho, et al.
Publicado: (2022)

Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate
por: Zgair, Atheer, et al.
Publicado: (2021)

Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study
por: Wiehle, Ronald, et al.
Publicado: (2013)

d-Chiro-Inositol improves testosterone levels in older hypogonadal men with low-normal testosterone: a pilot study
por: Nordio, Maurizio, et al.
Publicado: (2021)

Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials
por: Lachance, Sylvain, et al.
Publicado: (2015)

Anaphylaxis Triggered by Benzyl Benzoate in a Preparation of Depot Testosterone Undecanoate
por: Ong, Gregory S. Y., et al.
Publicado: (2012)

Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy
por: Dimitriadis, Georgios K., et al.
Publicado: (2018)

Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study
por: Chen, Yin-Wei, et al.
Publicado: (2019)

Symptomatic late-onset hypogonadism but normal total testosterone: the importance of testosterone annual decrease velocity
por: La Vignera, Sandro, et al.
Publicado: (2020)

Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone
por: Zucker, Isaac, et al.
Publicado: (2022)

Effects of Five-Year Treatment with Testosterone Undecanoate on Metabolic and Hormonal Parameters in Ageing Men with Metabolic Syndrome
por: Francomano, Davide, et al.
Publicado: (2014)

Testosterone replacement in male hypogonadism
por: Kalra, Sanjay, et al.
Publicado: (2010)

Testosterone Replacement Therapy and Bone Mineral Density in Men with Hypogonadism
por: Kim, Se Hwa
Publicado: (2014)

Cognitive effects of testosterone and finasteride administration in older hypogonadal men
por: Borst, Stephen E, et al.
Publicado: (2014)

Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men
por: Dadhich, Pranav, et al.
Publicado: (2017)

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
por: Ide, Veerle, et al.
Publicado: (2020)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

Prostate-Specific Antigen Concentrations in Response to Testosterone Treatment of Severely Hypogonadal Men
por: Sachdev, Saachi, et al.
Publicado: (2020)

SAT-052 A Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone to Eugonadal Levels with Fixed Dose Treatment
por: DelConte, Anthony, et al.
Publicado: (2020)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kifooe5knl5sm8to5sn274v3f